Onshoring a Clinical Biologic with Confidence
A strategic manufacturing transfer from a China-based CDMO to a trusted U.S. partner
Facing rising geopolitical risk, tariffs, and investor pressure to onshore, a U.S.-based biotech needed to relocate manufacturing for a Phase 1 monoclonal antibody without disrupting development timelines. With its program already produced at commercial-relevant scale overseas, the sponsor required a U.S. partner capable of executing a rapid, low-risk transition while preserving product quality.
This success story highlights how Avid Bioservices led a comprehensive process and analytical transfer, supported CGMP manufacturing, and mitigated global supply chain challenges. Through early cross‑functional engagement and a structured transfer framework, the program remained on track for key milestones while strengthening regulatory confidence and long-term commercial readiness.